Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean W Felsher

Showing results (71-80 of 146) with videos related to

Pageof 15
Sort By:
Analytical Chemistry|April 9, 2013
Characterization of MYC-induced tumorigenesis by in situ lipid profilingRichard H Perry, David I Bellovin, Emelyn H Shroff, et al.
Cancer Research|October 12, 2010
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cellsChristopher H Contag, Rachel Sikorski, Robert S Negrin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2019
Conditional Upregulation of IFN-α Alone Is Sufficient to Induce Systemic Lupus ErythematosusChieri Akiyama, Ken Tsumiyama, Chiaki Uchimura, et al.
Science (New York, N.Y.)|July 6, 2002
Sustained loss of a neoplastic phenotype by brief inactivation of MYCMeenakshi Jain, Constadina Arvanitis, Kenneth Chu, et al.
Molecular Cancer Therapeutics|July 5, 2013
A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanideHua Fan-Minogue, Sandhya Bodapati, David Solow-Cordero, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2017
Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinomaArvin M Gouw, Livia S Eberlin, Katherine Margulis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2011
Lymphomas that recur after MYC suppression continue to exhibit oncogene addictionPeter S Choi, Jan van Riggelen, Andrew J Gentles, et al.
Leukemia Research|September 20, 2011
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaMahesh Seetharam, Alice C Fan, Mai Tran, et al.
Cancer Biology & Therapy|July 31, 2007
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapySylvie Giuriato, Nathalie Faumont, Emilie Bousquet, et al.
Oncotarget|March 19, 2015
p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemiaAlper Yetil, Benedict Anchang, Arvin M Gouw, et al.
Pageof 15

Showing results (71-80 of 146) with videos related to

Sort By:
Pageof 15
Analytical Chemistry|April 9, 2013
Characterization of MYC-induced tumorigenesis by in situ lipid profilingRichard H Perry, David I Bellovin, Emelyn H Shroff, et al.
Cancer Research|October 12, 2010
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cellsChristopher H Contag, Rachel Sikorski, Robert S Negrin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2019
Conditional Upregulation of IFN-α Alone Is Sufficient to Induce Systemic Lupus ErythematosusChieri Akiyama, Ken Tsumiyama, Chiaki Uchimura, et al.
Science (New York, N.Y.)|July 6, 2002
Sustained loss of a neoplastic phenotype by brief inactivation of MYCMeenakshi Jain, Constadina Arvanitis, Kenneth Chu, et al.
Molecular Cancer Therapeutics|July 5, 2013
A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanideHua Fan-Minogue, Sandhya Bodapati, David Solow-Cordero, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2017
Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinomaArvin M Gouw, Livia S Eberlin, Katherine Margulis, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2011
Lymphomas that recur after MYC suppression continue to exhibit oncogene addictionPeter S Choi, Jan van Riggelen, Andrew J Gentles, et al.
Leukemia Research|September 20, 2011
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaMahesh Seetharam, Alice C Fan, Mai Tran, et al.
Cancer Biology & Therapy|July 31, 2007
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapySylvie Giuriato, Nathalie Faumont, Emilie Bousquet, et al.
Oncotarget|March 19, 2015
p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemiaAlper Yetil, Benedict Anchang, Arvin M Gouw, et al.
Pageof 15